Dianthus Therapeutics (NASDAQ:DNTH) Price Target Raised to $122.00

Dianthus Therapeutics (NASDAQ:DNTH) had its price target increased by analysts at Wedbush from $105.00 to $122.00 in a report released on Wednesday,Benzinga reports. The firm presently has an “outperform” rating on the stock. Wedbush’s price objective points to a potential upside of 9.99% from the company’s current price.

Other equities research analysts also recently issued research reports about the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Dianthus Therapeutics in a research note on Friday, July 17th. Wall Street Zen raised shares of Dianthus Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. TD Cowen restated a “buy” rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. Raymond James Financial restated a “strong-buy” rating on shares of Dianthus Therapeutics in a research report on Wednesday. Finally, Guggenheim reaffirmed a “buy” rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $119.36.

Dianthus Therapeutics Trading Up 4.6%

NASDAQ:DNTH opened at $110.92 on Wednesday. The business’s 50-day moving average is $93.50 and its 200 day moving average is $79.50. Dianthus Therapeutics has a 12 month low of $18.08 and a 12 month high of $114.55. The company has a market capitalization of $6.06 billion, a P/E ratio of -26.86 and a beta of 1.22.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by ($0.05). The firm had revenue of $0.76 million for the quarter, compared to analysts’ expectations of $0.30 million. Dianthus Therapeutics had a negative return on equity of 27.30% and a negative net margin of 12,998.50%. On average, research analysts forecast that Dianthus Therapeutics will post -3.82 earnings per share for the current year.

Insider Transactions at Dianthus Therapeutics

In related news, SVP Adam M. Veness sold 30,000 shares of the stock in a transaction dated Wednesday, June 17th. The shares were sold at an average price of $80.80, for a total value of $2,424,000.00. Following the sale, the senior vice president directly owned 30,000 shares of the company’s stock, valued at $2,424,000. This represents a 50.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Simrat Randhawa sold 26,530 shares of the firm’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $90.62, for a total transaction of $2,404,148.60. Following the completion of the sale, the executive vice president directly owned 4,000 shares of the company’s stock, valued at approximately $362,480. The trade was a 86.90% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 87,779 shares of company stock worth $7,985,235. 3.02% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. First Horizon Corp purchased a new stake in shares of Dianthus Therapeutics in the first quarter worth approximately $32,000. Caitong International Asset Management Co. Ltd purchased a new position in Dianthus Therapeutics during the 4th quarter valued at $40,000. Raymond James Financial Inc. purchased a new position in Dianthus Therapeutics during the 2nd quarter valued at $27,000. Russell Investments Group Ltd. bought a new position in Dianthus Therapeutics in the 3rd quarter valued at $64,000. Finally, ABS Direct Equity Fund LLC bought a new position in Dianthus Therapeutics in the 1st quarter valued at $179,000. Institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.